Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy.
In Hee LeeSoo Jung LeeJeeyeon LeeJin Hyang JungHo Yong ParkShin Young JeongSang-Woo LeeYee Soo ChaePublished in: BMC cancer (2020)
The results of this study suggest that 18F-FDG PET/CT pSUVmax is a predictive factor for pCR of HR-positive, HER2-negative breast cancer to NAC.